CCM
LABP

CAAS Capital Management’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

CAAS Capital Management’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,000
Closed -$385K – 1386
2021
Q1 		$385K Buy
+4,000
New +$522K ﹤0.01% 977

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAAS Capital Management's LABP Position: Q2 2021 in Review

CAAS Capital Management sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2021, closing a stake of 4,000 shares — an estimated $385K sold.

CAAS Capital Management first reported a position in LABP in Q1 2021 and held it in 1 quarter. The position peaked at $385K in Q1 2021. 33 funds tracked by Wall St. Rank hold LABP as of Q2 2021.

  • CAAS Capital Management reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 4,000 Landos Biopharma, Inc. Common Stock shares in Q2 2021, an estimated $385K.
  • CAAS Capital Management first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • CAAS Capital Management's Landos Biopharma, Inc. Common Stock position peaked at $385K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.